The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Immutep has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design.
read more
OncoSynergy announced the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of ...
read more
Pneumagen announced a further milestone in the development of Neumifil for the treatment of COVID-19.
read more
Breckenridge announced the FDA has granted final approval of its ANDA for Asenapine Sublingual Tablets in 5mg strength.
read more
Asceneuron announced the receipt of a $2.2 million award from the ADDF for a study of O-GlcNAcase inhibitor, ASN51.
read more
Immutep has announced the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the USPTO.
read more
4D Molecular Therapeutics announced the first patient has been dosed in the Phase 1/2 clinical trial of 4D-310 for the treatment of Fabry disease.
read more
Natera announced the first patient has been screened in a trial that uses Signatera as a companion diagnostic to identify MIUC patients eligible for ...
read more
Wednesday, March 17, 2021
Linnaeus announced the FDA has granted orphan drug designation for LNS8801 for the treatment of patients with MUM.
read more
Wednesday, March 17, 2021
Denali announced the FDA has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II).
read more
Nuvation Bio announced the FDA has granted Orphan Drug Designation to NUV-422 for the treatment of patients with malignant gliomas.
read more
Swedish Orphan Biovitrum announced the first patient has been dosed with avatrombopag for immune thrombocytopenia in pediatric patients.
read more
Regeneron and Sanofi announced positive results demonstrating an OS benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo ...
read more
TILT Biotherapeutics has achieved the primary endpoint of safety in its phase I trial with the first dose of its dual cytokine armed oncolytic ...
read more
AstraZeneca Pharmaceuticals
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a LAAB combination in late-...
read more